1 **Functional and quantitative evaluation of BNT162b2 SARS-CoV-2**

2 **vaccine-induced immunity**

3

4 Hitoshi Kawasuji,^a Yoshitomo Morinaga,^{b,c} Hideki Tani,^{b,d} Yumiko Saga,^{b,d} Makito

5 Kaneda,^a Yushi Murai,^a Akitoshi Ueno,^a Yuki Miyajima,^a Yasutaka Fukui,^a

6 Kentaro Nagaoka,^a Chikako Ono,^{e,f} Yoshiharu Matsuura,^{e,f} Hideki Niimi,^{c,g} and

7 Yoshihiro Yamamoto ^{a,c}

8

9 ^a Department of Clinical Infectious Diseases, Toyama University Graduate

10 School of Medicine and Pharmaceutical Sciences, Toyama, Japan

11 ^b Department of Microbiology, Toyama University Graduate School of Medicine

12 and Pharmaceutical Sciences, Toyama, Japan

13 ^c Clinical and Research Center for Infectious Diseases, Toyama University

14 Hospital, Toyama, Japan

15 ^d Department of Virology, Toyama Institute of Health, Toyama, Japan

16 ^e Laboratory of Virus Control, Center for Infectious Disease Education and

17 Research (CiDER), Osaka University, Osaka, Japan

^f Laboratory of Virus Control, Research Institute for Microbial
Diseases (RIMD), Osaka University, Osaka, Japan

^g Department of Clinical Laboratory and Molecular Pathology, Toyama University
Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan

22

23

24 **Corresponding author**

25 Yoshitomo Morinaga, MD, PhD

26 Department of Microbiology

27 Graduate School of Medicine and Pharmaceutical Sciences

28 University of Toyama

29 2630 Sugitani, Toyama 930-0194 Japan

30 Phone: +81-76-434-7256

31 Fax: +81-76-434-5020

32 E-mail: morinaga@med.u-toyama.ac.jp

33

34 **Key words:** neutralising antibodies; receptor-binding domain; variants;
35 high-throughput; systemic symptoms

36 **Abstract**

37 **Objectives**

38 Vaccines against severe acute respiratory syndrome coronavirus-2 have been
39 introduced. To investigate whether the vaccine provides protective immunity
40 effectively, the amount and function of vaccine-induced antibodies were
41 evaluated.

42 **Methods**

43 Sera from 13-17 days after the second dose of the Pfizer BNT162b2 vaccine
44 were collected from healthcare workers at the University of Toyama (n=740).
45 Antibody levels were quantitatively measured by the anti-receptor binding
46 domain antibody test (anti-RBD test), and neutralising activity against
47 pseudotyped viruses displaying wild-type (WT) and mutant spike proteins
48 (B.1.1.7- and B.1.351-derived variants) were assayed using a high-throughput
49 chemiluminescent reduction neutralising test (htCRNT). Basic clinical
50 characteristics were obtained from questionnaires.

51 **Results**

52 Antibodies were confirmed in all participants in both the anti-RBD test (median
53 2112 U/mL, interquartile range [IQR] 1275–3390 U/mL) and the htCRNT against

54 WT (median % inhibition >99.9, IQR >99.9 to >99.9). For randomly selected sera
 55 (n=61), 100.0% were positive for htCRNT against the B.1.1.7- and
 56 B.1.351-derived variants. Among those who answered the questionnaire
 57 (n=237), the values of the anti-RBD test were negatively correlated with age for
 58 females ($p < 0.01$; $r = -0.31$, 95% confidence interval -0.45 to -0.16). Systemic
 59 symptoms after vaccination were related to higher values of the anti-RBD test
 60 (median 2425, IQR 1450 – 3933 vs. median 1347, IQR 818 – 2125 for no
 61 symptoms; $p < 0.01$).

62 **Conclusions**

63 The BNT162b2 vaccine produced sufficient antibodies in terms of quality and
 64 quantity which could neutralise emerging variants. Antibody induction can be
 65 affected by age and sex but will still be at a sufficient level.

66 **Introduction**

67 Since severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
68 appeared in China, the COVID-19 pandemic has strongly limited our healthy
69 living and economic activity. There are still no therapeutic breakthroughs, but
70 vaccination is expected to be a specific and effective defence strategy to fight
71 COVID-19. Several vaccines against SARS-CoV-2 have been introduced, and to
72 date, vaccines manufactured by Pfizer (BNT162b2) have been administered in
73 Japan. This vaccine was shown to have preventive effects in 95% of individuals
74 against COVID-19 [1]; however, SARS-CoV-2 variants have emerged after the
75 report.

76 The B.1.1.7 variant, which originated in the United Kingdom, has a
77 mutation (N501Y) related to the increased affinity of the virus to the ACE2
78 receptor expressed on targeted cells [2]. The B.1.351 variant, which originated in
79 South Africa, has mutations K417N, E484K, and N501Y in the receptor binding
80 domain (RBD) of the spike (S) protein, which are related to reduced
81 neutralisation [3]. The effectiveness of the Pfizer vaccine against these emerging
82 variants has been reported to be similar to that of wild-type SARS-CoV-2 [4]. In
83 contrast, a reduction in the neutralisation potential of vaccinated sera against

84 variants has also been reported [5-7]. Therefore, a continuous evaluation of
85 vaccine efficacy is required.

86 Neutralising antibodies have protective functions against pathogens. We
87 previously established the chemiluminescence reduction neutralization test
88 (CRNT) for the evaluation of neutralising activity against SARS-CoV-2 using
89 pseudotyped virus [8]. The high-throughput CRNT (htCRNT), which is a modified
90 method using 384-well microplates, also has a good correlation with the CRNT
91 [8]. These methods assess the inhibition of infectivity in target cells. In contrast, it
92 is impossible to assess protective function directly by commercially available
93 antibody tests because they do not assess inhibition against viral infection.
94 However, some tests can provide quantitative values of antibodies and help us
95 to speculate on the state of acquired immunity. In this study, we confirmed that
96 the Elecsys Anti-SARS-CoV-2 S immunoassay, which is an anti-RBD antibody
97 test, and our neutralising tests are well-correlated and can effectively identify
98 convalescent COVID-19. These findings suggest that it is possible to
99 quantitatively and qualitatively evaluate antibodies against SARS-CoV-2 using
100 these two tests.

101 In confronting emerging variants, it is necessary to understand the

immunity acquired by the BNT162b2 vaccine. In the present study, sera after mass inoculation of healthcare workers were systematically obtained at our institute. Using two antibody assays, one quantitative and the other functional, the robustness and vulnerability of the immune status acquired by vaccination were investigated.

Materials and Methods

Collection of specimens

Serum samples were collected from healthcare workers at the Toyama University Hospital. All patients received two doses of the Pfizer BNT162b2 vaccine, and blood was drawn between 13-17 days after the second dose. The sera were used for serological assays on the day of blood collection or within 3 days of storage at 4°C. The remaining sera were frozen at -80°C until further verification.

Basic clinical characteristics were arbitrarily obtained from questionnaires. The following characteristics were obtained: age, sex, local symptoms after vaccination (pain at injection site, redness, swelling, hardness, local muscle pain, feeling of warmth, itching, and others), systemic symptoms

120 after vaccination (fever $\geq 37.5^{\circ}\text{C}$, general fatigue, headache, nasal discharge,
121 abdominal pain, nausea, diarrhoea, myalgia, joint pain, swelling of the lips and
122 face, hives, cough, and others), underlying diseases (malignant diseases,
123 hypertension, diabetes, dyslipidaemia, renal failure, liver failure, asthma,
124 autoimmune diseases, and others), and medications (corticosteroids excluding
125 ointment, immunosuppressants, anti-tumour drugs, anti-rheumatoid drugs, and
126 radiological therapy).

127

128 ***Generation of pseudotyped viruses***

129 Pseudotyped vesicular stomatitis virus (VSV) bearing SARS-CoV-2 S protein
130 was generated as previously described [8, 9]. The expression plasmid for the
131 truncated S protein of SARS-CoV-2, pCAG-SARS-CoV-2 S (Wuhan), was kindly
132 provided by Dr. Shuetsu Fukushi, National Institute of Infectious Diseases,
133 Japan. The expression plasmids for the truncated mutant S protein of
134 SARS-CoV-2, pCAGG-pm3-SARS2-Shu-d19-B1.1.7 (B.1.1.7-derived variant),
135 and pCAGG-pm3-SARS2-Shu-d19-B1.351 (B.1.351-derived variant), were
136 constructed by PCR-based site-directed mutagenesis using cDNA as a template,
137 which was obtained by chemical synthesis with optimisation for the humanised

138 codon (Thermo Fisher Scientific, Waltham, MA). S cDNA of SARS-CoV-2 was
139 cloned into the pCAGGS-pm3 expression vector. Briefly, 293T cells were
140 transfected with the above expression vectors. After 24 h of incubation, the
141 transfected cells were infected with G-complemented (*G) VSV Δ G/Luc
142 (*G-VSV Δ G/Luc) at a multiplicity of infection of 0.5. The virus was adsorbed and
143 extensively washed four times with Dulbecco's modified Eagle's medium
144 (DMEM) supplemented with 10% foetal bovine serum (FBS). After 24 h of
145 incubation, the culture supernatants containing pseudotyped VSVs were
146 centrifuged to remove cell debris and stored at -80°C until further use.

147

148 ***Serological tests***

149 The neutralising effects of samples against pseudotyped viruses were examined
150 in 384-well microplates (Corning Inc., Corning, NY) using the htCRNT, as
151 previously described. In this study, we utilized VeroE6/TMPRSS2 cells, which
152 are highly susceptible to SARS-CoV-2 infection. VeroE6/TMPRSS2 cells
153 (JCRB1819) were purchased from the Japanese Collection of Research
154 Bioresources (JCRB) Cell Bank (Osaka, Japan). Briefly, 100-fold diluted
155 serum-containing DMEM (Nacalai Tesque, Inc., Kyoto, Japan) with 10%

156 heat-inactivated FBS was incubated with pseudotyped SARS-CoV-2 for 1 h.
157 After incubation, VeroE6/TMPRSS2 cells were treated with DMEM-containing
158 serum and pseudotyped virus. The infectivity of the pseudotyped viruses was
159 determined by measuring the luciferase activity after 24 h of incubation at 37°C.
160 A score with $\geq 50\%$ inhibition of viral infection was considered positive for
161 neutralisation.

162 For the commercial assay, serum samples were tested at Toyama
163 University Hospital using the Elecsys Anti-SARS-CoV-2 S immunoassay (Roche
164 Diagnostics GmbH, Basel, Switzerland) to quantitatively measure antibody
165 levels against SARS-CoV-2 RBD. The manufacturer's cut-off value (COV) was
166 0.8 U/mL and the minimum value was expressed as <0.4 U/mL.

167

168 ***Statistical analysis***

169 Statistical analysis was performed using the Mann-Whitney test to compare
170 non-parametric groups. The Friedman test with Dunn's test was used for multiple
171 comparisons among the three paired groups. Correlations between test findings
172 were expressed using Pearson's correlation coefficients. Data were analysed
173 using GraphPad Prism version 8.4.3 (GraphPad Software, San Diego, CA).

174 Statistical significance between different groups was defined as $P < 0.05$. Data
175 are expressed as medians with interquartile ranges (IQR).

176

177 ***Ethics approval***

178 This study was performed in accordance with the Declaration of Helsinki and
179 was approved by the ethical review board of the University of Toyama (approval
180 No.: R2019167). Written informed consent was obtained from all participants.

181

182 **Results**

183 ***Antibody quantification and neutralising activity after vaccination***

184 Serum samples were obtained from a total of 740 participants. All participants
185 were positive for the htCRNT and anti-RBD antibody tests (**Fig 1**). All htCRNT
186 values were over 80.0% (range, 80.6-100.0), and the median was >99.9% (IQR
187 >99.9 to >99.9). For the anti-RBD antibody test, the range and median were
188 28.5-10824 U/mL and 2112 U/mL (IQR 1275–3390 U/mL), respectively.

189 Next, 61 representative samples were randomly selected and assayed
190 using pseudotyped B.1.1.7 and B.1.351-derived variants. Of these, 100.0%
191 (61/61) were positive for htCRNT against both variants. Compared to the

192 wild-type (median >99.9; IQR >99.9 to >99.9), the htCRNT values against the
193 B.1.1.7 and B.1.351-derived variants were significantly decreased (median 97.8,
194 IQR 90.9 - >99.9 and median 96.9, IQR 89.0 - 99.2, respectively; $p < 0.01$) (**Fig**
195 **2A**). The values of the htCRNT against the B.1.1.7 and B.1.351-derived variants
196 were positively correlated with the values of the anti-RBD antibody test ($r = 0.44$,
197 95% confidence interval [CI] 0.21-0.62 and $r = 0.40$, 95% CI 0.17-0.60,
198 respectively) (**Fig 2B**).

199

200 ***Relationship between vaccine-induced antibody and demographic*** 201 ***characteristics***

202 Finally, demographic characteristics were obtained from participants who
203 answered the questionnaire and their test results were compared. A total of 237
204 participants provided their ages and symptoms after vaccination (**Table 1**). Of
205 these, 21 had data with neutralisation against the variants.

206 The values of the anti-RBD antibody test in females (median 2345, IQR
207 1388–3960) were significantly higher than those in males (median 1967, IQR
208 1086–2849; $p < 0.05$) (**Fig 3A**) and were negatively correlated with age for
209 females ($r = -0.31$, 95% CI -0.45 to -0.16; $p < 0.01$) but not for males ($r = -0.08$;

210 95% CI -0.29 to 0.14; $p=0.47$) (**Fig 3B**). For the neutralisation, while the values
 211 of htCRNT against the wild-type were not correlated with age, those against the
 212 variants decreased in an age-dependent manner, with the B.1.351-derived
 213 variant showing significance (B.1.1.7-derived variant: $p = 0.07$, $r = -0.40$, 95% CI
 214 -0.71 to 0.03; B.1.351-derived variant, $p < 0.01$, $r = -0.57$, 95% CI -0.81 to 0.19)
 215 (**Fig 3C**).

216 The systemic symptoms after vaccination related to the anti-RBD
 217 antibody levels and the number of individuals without systemic symptoms
 218 significantly decreased compared with those with systemic symptoms (with
 219 systemic symptoms: median 2426, IQR 1450–3933 vs. without systemic
 220 symptoms: median 1347, IQR 818–2125; $p<0.01$) (**Fig 3D**). There was no
 221 significant change in local symptoms. For individuals with underlying diseases or
 222 medications, there were no significant differences in anti-RBD antibody levels.

223

224 Discussion

225 After BNT162b2 vaccination, sufficient antibodies in terms of both quality and
 226 quantity were acquired. Surprisingly, compared with our previous findings in
 227 convalescent COVID-19 (CRNT, median 83.5, IQR 64.1–90.0; anti-RBD

228 antibody test, median 35.0, IQR 7.63–137.0) [8], the amount of the anti-RBD
229 antibody was 60.3-fold elevated and vaccinated sera neutralised pseudotyped
230 viral infection almost completely. These findings suggest that the BNT162b2
231 vaccine can provide sufficient antibodies that surpass the immunity acquired by
232 natural infection. In addition, individuals who have recovered from COVID-19
233 have generated some protective immunity; however, the vaccine can enhance
234 their immune responses.

235 Similar to previous reports [4, 6], our findings support the notion that
236 vaccinated sera can cross-react with SARS-CoV-2 variants. The reduction in
237 neutralisation against the B.1.351 variant has been widely recognized [7, 10];
238 however, for the B.1.1.7 variant, some reports indicated that the neutralisation
239 activity is similar to that of the wild-type [6, 11] and some reported a reduced
240 level compared to the wild-type [4, 5, 12]. In the present study, although the
241 neutralisation against variants was significantly reduced compared to the
242 wild-type, almost all sera still had a >50% inhibitory effect. Because
243 approximately half of the convalescent sera did not show >50% inhibition in our
244 previous study, vaccine-induced antibodies are likely to be more effective
245 against variants than infection-induced antibodies. In addition, efficacy against

246 variants seems to be quantitatively related with a larger amount of the antibody
247 induced by the vaccine.

248 Sex differences were observed, where females developed higher
249 antibody levels in vaccine-induced immunity. Similar differences in vaccination
250 have also been reported in previous reports [13, 14]. The acquisition of antibody
251 levels was reduced in an age-dependent manner in females. Similarly,
252 age-related reduction was indicated after BNT162b2 vaccination using another
253 commercial antibody test [15]. These findings are consistent with a general
254 understanding of vaccinated immunity [16]. An important aspect of the present
255 study is that it shows sufficient immunity even for the oldest participants.
256 However, because this study did not include elderly people, further examination
257 will be necessary. Neutralisation against variants was maintained at >50%
258 inhibition but showed age-dependent reduction. There was a significant
259 difference only against the B.1.351-derived variant; however, it is reasonable to
260 think that both the B.1.1.7- and B.1.351-derived variants tend to be similar.
261 Meanwhile, it remains unknown how much a reduction in neutralisation will
262 impact one's future risk of COVID-19. Whether these findings in age and sex
263 have clinical impact should be monitored in the future; however, cross-reaction

264 to variants can support secondary immunity.

265 The limitations of the current study are as follows. The efficacy of
266 SARS-CoV-2 vaccination among people whose immunity may be unstable, such
267 as children, elderly people, and individuals with underlying diseases, is unknown.
268 It is still unknown how long immunity is maintained after vaccination. Therefore,
269 we plan to conduct a follow-up study for the participants. Lastly, it is impossible
270 to exclude possible participants who had already acquired immunity because
271 sera prior to vaccination were not assessed.

272 In conclusion, the BNT162b2 vaccine produced a sufficient level of
273 antibodies with a neutralising effect against WT SARS-CoV-2 and emerging
274 variants. Antibody induction can be affected by age and sex but is still induced to
275 a sufficient level.

276

277 **Transparency declaration**

278 **Conflicts of interest**

279 The authors have no conflicts of interest to declare.

280 **Funding**

281 This study was supported by the Research Program on Emerging and
282 Re-emerging Infectious Diseases from AMED Grant No. JP20he0622035 (YM,
283 HT, and YY) and the Research Funding Grant by the president of the University
284 of Toyama (YM, NH, and YY).

285 **Acknowledgments**

286 We thank all the staff at Toyama University Hospital for their help in collecting
287 specimens and questionnaires. We would like to thank Mayu Somekawa for the
288 arrangement of the specimens.

289 **Contribution**

290 Conceptualization YMo

291 Methodology HK, YMo, HT

292 Validation HK, YMo

293 Formal Analysis HK, YMo

294 Investigation HK, YMo, MK, and YuMu (neutralising assay)

295 HN (commercial antibody test)

296 **Resources** HT, TS, EI, YS (generating pseudotyped viruses)

297 CO, YMa (generating plasmids)

298 HK, MK, YMu, AU, YMi, YF, and KN (serum sample

299 collection)

300 **Data Curation** HK, YMo

301 **Writing – Original Draft Preparation** HK, YMo, HT

302 **Writing – Review and Editing** HK, YMo, HT

303 **Visualization** YMo

304 **Supervision** YMa, HN, YoYa

305 **Project Administration** YMo, YYa

306 **Funding** YMo, HT, HN, YYa

307

308

309 **Table 1. Demographic and clinical characteristics of the study participants**
 310 **who answered the questionnaire**

311

Profile	Answered individuals, n=237
Sex, male, n (%)	85 (35.9)
Age, years, n (%)	
20-24	10 (4.2)
25-29	30 (12.7)
30-34	40 (16.9)
35-39	20 (8.4)
40-44	46 (19.4)
45-49	28 (11.8)
50-54	19 (8.0)
55-59	23 (9.7)
60-64	19 (8.0)
≥65	2 (0.8)
Symptom, n (%)	
Local symptom	204 (86.1)

Systemic symptom	202 (85.2)
Underlying diseases, YES, n (%)	43 (18.1)
Medication, YES, n(%)	8 (3.4)

312

313

Figure 1 Relationship between anti-RBD antibody levels and neutralisation

Neutralisation levels against pseudotyped viruses measured by htCRNT (blue) and anti-RBD antibody levels measured by a commercially available test (pink) were plotted (n=740). The results of both tests are plotted on the XY coordinate (purple). The value of htCRNT is the mean of duplicate assays using 100-fold diluted serum. Bars indicate medians with interquartile ranges. htCRNT, high-throughput chemiluminescent reduction neutralising test; RBD, receptor-binding domain.

Figure 2 Cross-reaction against B.1.1.7 and B.1.351-derived variants in representative sera

(A) Neutralising activity against wild-type (WT), B.1.1.7-, and B.1.351-derived variants (n=61). (B) The relationship between neutralising activity and anti-RBD antibody levels.

******, $p < 0.01$. Bars indicate medians with interquartile ranges.

332 **Figure 3 Relationship of the vaccine-induced antibody and demographic**

333 **characteristics in questionnaire-answered population**

334 (A) Anti-RBD antibody levels in males and females (n=237). (B) Relationship
335 between anti-RBD antibody levels and age. (C) Relationship between htCRNT
336 levels and age (for WT pseudotyped virus; n= 237, for B.1.1.7- and
337 B.1.351-derived variants; n = 21). (D) Anti-RBD antibody levels and local or
338 systemic symptoms.

339 *, p < 0.05, **, p < 0.01, ns; not significance. Bars indicate medians with
340 interquartile ranges. RBD, receptor-binding domain; htCRNT, high-throughput
341 chemiluminescent reduction neutralising test.

342

343 **References**

344

- 345 [1] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez
346 JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury
347 S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Jr., Hammitt LL, Türeci Ö,
348 Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U,
349 Jansen KU, Gruber WC. Safety and Efficacy of the BNT162b2 mRNA Covid-19
350 Vaccine. *New England J Med* 2020; 383: 2603-2615.
- 351 [2] Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KH, Dingens AS, Navarro
352 MJ, Bowen JE, Tortorici MA, Walls AC. Deep mutational scanning of
353 SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2
354 binding. *Cell* 2020; 182: 1295-1310. e20.
- 355 [3] Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, Robinson ML, Sie
356 BM, Li MZ, Chen Y. Viral epitope profiling of COVID-19 patients reveals
357 cross-reactivity and correlates of severity. *Science* 2020 in press.
- 358 [4] Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA,
359 Cutler M, Cooper D, Menachery VD, Weaver SC, Dormitzer PR, Shi PY.
360 Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants
361 by BNT162b2 vaccine-elicited sera. *Nat Med* 2021; 27: 620-621.
- 362 [5] Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, Zhao Y,
363 Duyvesteyn HM, Nutalai R, Tuekprakhon A. Reduced neutralization of
364 SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera. *Cell* 2021 in
365 press.
- 366 [6] Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm-Cohen L, Raviv Y,
367 Shemer-Avni Y, Rosenberg E, Taube R. SARS-CoV-2 spike variants exhibit
368 differential infectivity and neutralization resistance to convalescent or
369 post-vaccination sera. *Cell Host Microb* 2021; 29: 522-528.e2.
- 370 [7] Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH,
371 Mantus G, Nyhoff LE, Adelman MW, Fineman R, Patel S, Byram R, Gomes DN,
372 Michael G, Abdullahi H, Beydoun N, Panganiban B, McNair N, Hellmeister K,
373 Pitts J, Winters J, Kleinhenz J, Usher J, O'Keefe JB, Piantadosi A, Waggoner JJ,
374 Babiker A, Stephens DS, Anderson EJ, Edupuganti S, Roupheal N, Ahmed R,
375 Wrammert J, Suthar MS. Infection- and vaccine-induced antibody binding and
376 neutralization of the B.1.351 SARS-CoV-2 variant. *Cell Host Microb* 2021; 29:

- 377 516-521.e3.
- 378 [8] Morinaga Y, Tani H, Terasaki Y, Nomura S, Kawasuji H, Shimada T, Igarashi E,
379 Saga Y, Yoshida Y, Yasukochi R, Kaneda M, Murai Y, Ueno A, Miyajima Y, Fukui
380 Y, Nagaoka K, Ono C, Matsuura Y, Fujimura T, Ishida Y, Oishi K, Yamamoto Y.
381 Correlation of the commercial anti-SARS-CoV-2 receptor binding domain
382 antibody test with the chemiluminescent reduction neutralizing test and possible
383 detection of antibodies to emerging variants. medRxiv in preperation.
- 384 [9] Tani H, Kimura M, Tan L, Yoshida Y, Ozawa T, Kishi H, Fukushima S, Saijo M,
385 Sano K, Suzuki T, Kawasuji H, Ueno A, Miyajima Y, Fukui Y, Sakamaki I,
386 Yamamoto Y, Morinaga Y. Evaluation of SARS-CoV-2 neutralizing antibodies
387 using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
388 Virology J 2021; 18: 16.
- 389 [10] Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, Krüger N,
390 Graichen L, Hofmann-Winkler H, Kempf A, Winkler MS, Schulz S, Jäck HM,
391 Jahrsdörfer B, Schrezenmeier H, Müller M, Kleger A, Münch J, Pöhlmann S.
392 SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell
393 2021 in press.
- 394 [11] Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F,
395 Planchais C, Buchrieser J, Rajah MM, Bishop E, Albert M, Donati F, Prot M,
396 Behillil S, Enouf V, Maquart M, Smati-Lafarge M, Varon E, Schortgen F,
397 Yahyaoui L, Gonzalez M, De Sèze J, Péré H, Veyer D, Sève A, Simon-Lorière E,
398 Fafi-Kremer S, Stefic K, Mouquet H, Hocqueloux L, van der Werf S, Prazuck T,
399 Schwartz O. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants
400 to neutralizing antibodies. Nat Med 2021 in press.
- 401 [12] Bates TA, Leier HC, Lyski ZL, McBride SK, Coulter FJ, Weinstein JB,
402 Goodman JR, Lu Z, Siegel SAR, Sullivan P, Strnad M, Brunton AE, Lee DX,
403 Curlin ME, Messer WB, Tafesse FG. Neutralization of SARS-CoV-2 variants by
404 convalescent and vaccinated serum. medRxiv 2021 DOI
405 10.1101/2021.04.04.21254881.
- 406 [13] Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences
407 in vaccine-induced humoral immunity. Semin Immunopathol 2019; 41: 239-249.
- 408 [14] Fink AL, Engle K, Ursin RL, Tang WY, Klein SL. Biological sex affects
409 vaccine efficacy and protection against influenza in mice. PNAS 2018; 115:
410 12477-12482.
- 411 [15] Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J,
412 Hillebrandt J, Ritchie A, Rabl D, Ostermann PN, Robitzsch R, Hauka S, Walker A,

413 Menne C, Grutza R, Timm J, Adams O, Schaal H. Age-dependent immune
414 response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. medRxiv
415 2021 DOI 10.1101/2021.03.03.21251066.
416 [16] Blomberg BB, Frasca D. Quantity, not quality, of antibody response
417 decreased in the elderly. J Clin Invest 2011; 121: 2981-3.
418

Figure 1

Figure 2

Figure 3